CN107669711A - The preparation method and its usage of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract - Google Patents
The preparation method and its usage of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract Download PDFInfo
- Publication number
- CN107669711A CN107669711A CN201711180533.2A CN201711180533A CN107669711A CN 107669711 A CN107669711 A CN 107669711A CN 201711180533 A CN201711180533 A CN 201711180533A CN 107669711 A CN107669711 A CN 107669711A
- Authority
- CN
- China
- Prior art keywords
- extract
- pers
- wallr
- pat
- ganoderma applanatum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention disclose a kind of preparation method of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract, and methods described uses the mixed solvent of ethanol, water or second alcohol and water as solvent extraction artist's conk, the problem of in the absence of organic solvent pollution or residual, safety and environmental protection.There is the Ganoderma applanatum (Pers. Ex Wallr) Pat. extract being prepared using the method for the invention significant anti-trioxypurine to act on, and Small side effects, can be used in preparing the medicine for alleviating gout illness, and new direction is provided to improve the big phenomenon of current goat drug side-effect.
Description
Technical field
The present invention relates to the new application of a kind of preparation method of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract and Ganoderma applanatum (Pers. Ex Wallr) Pat. extract in anti-trioxypurine, belong to
Health products and the field of Chinese medicines.
Background technology
Goat seriously perplexs human lives, and the epidemiological study of New Zealand, the U.S. and China shows that gout illness becomes
Must be more and more common, the incidence of disease is about 2%, and is constantly raised.Wherein 65 years old and above crowd's incidence highest, the morbidity of male
Rate is also higher twice than the women incidence of disease.Goat is the result of hyperuricemia development, is due to that internal uric acid concentration is higher than blood
Liquid solvability (>360 μm of ol/L), cause sodium urate crystals to be deposited in soft tissue, joint, these depositing crystallines cause soft group
Knit, inflammatory has an intense pain repeatedly for joint and bone tissue, seriously reduce patients ' life quality.
Goat is divided into acute and chronic two kinds.Resist in the market for acute gout disease medicine including non-steroidal
Scorching medicine, colchicine, corticotropin or steroids, these medicines mainly act on inflammatory factor, reduce patient
Pain.For chronic gout disease, management blood uric acid levels are crucial.At present, for reducing the medicine of uric acid concentration in human body
Mainly have：Allopurinol, medicine for improving uric acid excretion and diuretic, including the uric acid that Benzbromarone, uricase, PEG are modified
Enzyme etc., these medicines to liver and kidney metabolic organ because there is stronger side effect to prevent the patient with hepatopathy and nephrosis from making
With, while these medicines easily trigger intestines and stomach and cardiovascular disease.This cause with hypertension, congestive heart failure, gastritis,
The patient with gout of ulcer or renal insufficiency, which takes said medicine, generally has higher risk.Chinese Herbs are good, side effect
Low, its advantage gradually shows, thus clinically widely uses.Therefore, the Chinese medicine with anti-trioxypurine effect is found with important
Meaning.
Ganoderma lipsiense [Ganodermaapplanatum (Pers.) Pat], the flat ganoderma lucidum of alias artist's conk, artist's conk, ganoderma applanatum,
Belong to Basidiomycota, Aphyllophorales, ganoderma lucidum Cordycepps, Ganoderma.Ganoderma lipsiense is exactly a kind of medicinal fungi since ancient times, and its taste is micro-
Bitter, flat, returns spleen, stomach, medical value is high,《Chinese medicinal fungi illustrated handbook》With《Plants from Changbai Mountain Area medicine will》In on the books, energy
Dispelling wind and eliminating dampness, heat-clearing, analgesic, change product, hemostasis, resolving sputum, is that one kind treats acute and chronic hepatitis, peptic ulcer, early stage liver
Hardening and the disease such as rheumatic pulmonary tuberculosis and the medicine with nourishing function, it is also among the people as cancer therapy drug in China and Japan
Using a very long time.Clinic is used for treating hepatitis B, cancer of the esophagus, pulmonary tuberculosis, neurasthenia etc..
The content of the invention
For above-mentioned prior art, it is an object of the invention to provide a kind of new preparation process of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract, simultaneously
The present invention also provides a kind of new application of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract in anti-trioxypurine.
To achieve the above object, the technical scheme taken of the present invention is：A kind of preparation method of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract, including with
Lower step：
(1) dry artist's conk fructification is crushed；
(2) 0.5-5 hours are extracted with 5-25 times of ethanol at 40-75 DEG C, is filtered under diminished pressure separation filter residue and filtrate, repeat three
It is secondary；
(3) it is evaporated under reduced pressure after the filtrate obtained by step (2) is merged and is concentrated into 25-250mL, alcohol extract is obtained after drying；
(4) 40-100 DEG C by the use of water as solvent extraction alcohol extracting after artist's conk residue 0.5-3 hours, after be filtered under diminished pressure separation
Filter residue and filtrate, identical condition is in triplicate；
(5) it is evaporated under reduced pressure after the filtrate obtained by step (4) is merged and is concentrated into 25-250mL, water extract is obtained after drying.
The preparation method of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract of the present invention, using aboundresources, cheap, environment-friendly ethanol,
Water or ethanol and aqueous mixtures reach the purpose for reducing production cost, avoiding organic solvent pollution as solvent.
As the preferred embodiment of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract preparation method of the present invention, the extraction temperature in the step (2)
Spend for 60 DEG C；Extracting temperature in step (4) is 85 DEG C.
As the preferred embodiment of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract preparation method of the present invention, carrying in the step (2) and (4)
It is ultrasonic extraction to take process.
In addition, present invention also offers a kind of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract, the Ganoderma applanatum (Pers. Ex Wallr) Pat. extract uses preparation method as described above
It is prepared.
Anti-trioxypurine experiment in Mice Body is carried out using Ganoderma applanatum (Pers. Ex Wallr) Pat. extract made from the above method, the results showed that is extracted with artist's conk
Thing continuous gavage 7 days, the blood uric acid concentration of high lithemia mouse can be fallen below normal mouse uric acid level.
As the preferred embodiment of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract of the present invention, in the Ganoderma applanatum (Pers. Ex Wallr) Pat. extract, triterpene total content is
100~10000 μ g/g.
Secondly, present invention also offers Ganoderma applanatum (Pers. Ex Wallr) Pat. extract prepare anti-trioxypurine, improve the medicine of gout illness, health products or
Application in ancillary drug.
As Ganoderma applanatum (Pers. Ex Wallr) Pat. extract of the present invention in medicine, health products or the auxiliary for preparing anti-trioxypurine, improving gout illness
The preferred embodiment of application in medicine, the Ganoderma applanatum (Pers. Ex Wallr) Pat. extract are prepared with the following method：
(1) dry artist's conk fructification is crushed；
(2) 0.5-5 hours are extracted with 5-25 times of ethanol at 40-75 DEG C, is filtered under diminished pressure separation filter residue and filtrate, repeat three
It is secondary；
(3) it is evaporated under reduced pressure after the filtrate obtained by step (2) is merged and is concentrated into 25-250mL, alcohol extract is obtained after drying；
(4) 40-100 DEG C by the use of water as solvent extraction alcohol extracting after artist's conk residue 0.5-3 hours, after be filtered under diminished pressure separation
Filter residue and filtrate, identical condition is in triplicate；
(5) it is evaporated under reduced pressure after the filtrate obtained by step (4) is merged and is concentrated into 25-250mL, water extract is obtained after drying.
As Ganoderma applanatum (Pers. Ex Wallr) Pat. extract of the present invention in medicine, health products or the auxiliary for preparing anti-trioxypurine, improving gout illness
The preferred embodiment of application in medicine, the Extracting temperature in rapid (2) is 60 DEG C；Extracting temperature in step (4) is
85℃。
As Ganoderma applanatum (Pers. Ex Wallr) Pat. extract of the present invention in medicine, health products or the auxiliary for preparing anti-trioxypurine, improving gout illness
The preferred embodiment of application in medicine, the extraction process in the step (2) and (4) is ultrasonic extraction.
Finally, present invention also offers a kind of medicine for treating goat, the medicine contains artist's conk as described above and carried
Take thing.
The beneficial effects of the present invention are：The preparation method of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract provided by the invention, technique is simple, cost
It is low；Using the mixed solvent of ethanol, water or second alcohol and water as solvent extraction artist's conk, in the absence of organic solvent pollution or residual
The problem of, safety and environmental protection.There is the Ganoderma applanatum (Pers. Ex Wallr) Pat. extract being prepared using the method for the invention significant anti-trioxypurine to act on, and
It Small side effects, can be used in preparing the medicine for alleviating gout illness, carried to improve the big phenomenon of current goat drug side-effect
New direction is supplied.
Brief description of the drawings
Fig. 1 is each group mice serum uric acid level；
Fig. 2 is each group mouse urine uric acid level；
Fig. 3 is each group mice serum urea nitrogen levels；
Fig. 4 is each group mouse urine urea nitrogen levels；
Fig. 5 is each group mice serum creatinine level；
Fig. 6 is each group mouse urine creatinine level；
Fig. 7 changes for each group mouse weight；
Fig. 8 is each group mouse liver coefficient；
Fig. 9 is each group Mouse Kidney coefficient；
Figure 10 is each group mice spleen coefficient；
Figure 11 is each group mouse liver XOD activity；
Figure 12 is each group mice serum XOD activity；
Figure 13 is the expression that Mouse Kidney ion transporter is detected using Western blot；
Figure 14 is OAT1 protein expression level；
Figure 15 is GLUT9 protein expression level；
Figure 16 is URAT1 protein expression level；
Figure 17 is the expression that mouse intestinal transport protein is detected using Western blot；
Figure 18 is CNT2 protein expression level.
Embodiment
To better illustrate the object, technical solutions and advantages of the present invention, below in conjunction with specific embodiment to the present invention
It is described further.
Embodiment 1
The preparation of artist's conk ethanol extract
Artist's conk fructification 100g is taken, is added after being crushed using pulverizer in conical flask, and adds 2L ethanol, mixture is existed
Filtered after water-bath is extracted 3 hours at 65 DEG C using 400 mesh filter screens.Extraction experiment in triplicate, is depressurized after gained filtrate is merged
Distillation and concentration is lyophilized to obtain artist's conk ethanol extract (GAE) 3.78g, yield 3.78% to 25mL.
Embodiment 2
The preparation of artist's conk water extract
In 85 DEG C of water-bath by the use of 2L water as solvent extraction alcohol extracting after artist's conk residue 3 hours, after be filtered under diminished pressure separation
Filter residue and filtrate, extraction experiment in triplicate, are evaporated under reduced pressure after gained filtrate is merged and are concentrated into 25mL, and freeze and obtain water extraction
Take thing (GAW) 8.53g, yield 8.53%.
Embodiment 3
Triterpene determines in Ganoderma applanatum (Pers. Ex Wallr) Pat. extract
Total triterpene contentses are determined using HPLC methods, wherein the phosphate aqueous solution gradient elution of (A) second eyeball one (B) 0.03%, stream
Speed is 1mL/min, and Detection wavelength 252nm, column temperature is 29 DEG C, and it is 1097 to measure triterpene content in above-mentioned artist's conk ethanol extract
μg/g。
Embodiment 4
Ganoderma applanatum (Pers. Ex Wallr) Pat. extract anti-trioxypurine is tested
(1) 100 male SPF kunming mices (20 ± 2g) are taken, are randomly divided into 10 groups：Normal group, hyperuricemia
Model group, allopurinol and the artist's conk alcohol extract experimental group and artist's conk water extract of Benzbromarone control and high, medium and low dosage are real
Test a group administration group.Except Normal group intraperitoneal injection and gavage distilled water in addition to, other groups according to 250mg/kg/d dosage abdominal cavity
Inject Oxonic Acid sylvite, while the hypoxanthine modeling of gavage 500mg/kg/d dosage.Water is can't help in the previous hour fasting of modeling,
1 hour after modeling, allopurinol and benzene bromine horse are given with allopurinol (5mg/kg) and Benzbromarone (7.8mg/kg) gastric infusion
The mouse of grand control.For medicine group, basic, normal, high artist's conk alcohol extract experimental group is respectively with the reality of 30,60,120mg/kg concentration
Apply artist's conk ethanol extract made from example 1 and carry out gastric infusion by 100mg/kg/d dosage；Basic, normal, high artist's conk alcohol extract is real
Group is tested respectively with artist's conk ethanol extract made from the embodiment 2 of 30,60,120mg/kg concentration by 100mg/kg/d dosage to enter
The pure water of row gastric infusion, Normal group and hyperuricemia model control group then gavage same volume, continuous 7 days, and
1st, 3,5,7 day record of being weighed to mouse.
For (2) the 7th days gastric infusions after 1 hour, execution takes blood and urine to be centrifuged using centrifuge under 3500r/min speed
The isolated serum of blood sample obtained by 10min is stored in -20 DEG C.Extract mice organs official, including liver, spleen, kidney.And
Washed with normal saline solution.Then blotted, weighed with plain filter.
(3) take in (2) gained serum and urine to determine serum uric acid level respectively, urine uric acid level, serum urea and
Creatinine level and urine urea and creatinine level.
(4) internal organs obtained by (2) are taken by the way that the body weight of single mouse divided by the weight of each organ of single mouse are counted
Calculate acropetal coefficient's (liver coefficient, Spleen coefficient and Kidney coefficients).Hepatectomize and renal tissue, weigh and use cold saline
(0.9%) homogeneous, and centrifuged 10 minutes with 2,400rpm at 4 DEG C.Supernatant is preserved for XOD activity analysis and Western prints
Mark is analyzed.
(5) serum and gained hepatic tissue liquid in (4) determine serum respectively as obtained by ELISA kit colorimetric method (2)
With liver XOD activity.
(6) kidney samples A carries out Western blot analysis.With GAPDH (glyceraldehyde-3-phosphate dehydrogenase) for internal reference, inspection
Survey includes URAT1 (urate transporter 1), OAT1 (organic anion transporter 1), GLUT9 (GLUT 9) etc.
The expression of albumen.
(7) statistical analysis is carried out using expert data processing routine SPSS (Release 11.5, SPSS Inc., 2001).
All data are expressed as mean+/-standard error (S.D.), and are analyzed by one-way analysis of variance (ANOVA), and lead to
Cross double tail Student's t and examine and compare cell mean.Statistically significant (the P of difference<0.05 or P<0.01) the following symbol of use
Number represent：Compareed with normal group variant：*P<0.05, * * P<0.01；Compareed with the PO and HX hyperuricemia model groups induced
It is variant, #P<0.05, ##P<0.01；Variant, △ P are compareed with allopurinol group<0.05, △ △ P<0.01.
Blood uric acid is the direct indicator for evaluating anti-trioxypurine effect, as a result as shown in Figure 1.Oteracil Potassium and hypoxanthine joint
Administration causes hyperuricemia model group serum uric acid level to raise, compared with normal mouse (145 μm of ol/L), hyperuricemia
Mouse (P<0.01) it is significant to be increased to 342 μm of ol/L, illustrate modeling success.Allopurinol (98mol/L, P<And benzene bromine horse 0.01)
Grand (181 μm of ol/L, P<0.01) serum uric acid level of control group declines the success that also demonstrate that hyperuricemia modeling.Important
Be, 30,60 and 120mg/kg dosage GAE administration groups in, the serum uric acid level of antihyperuricemic mouse drops to 185 respectively,
178 and 159 μm of ol/L (P<0.01).In addition, dosages of the GAW in 30,60 and 120mg/kg causes hyperuricemia mouse
Serum uric acid level be reduced to 204,195 and 182 μm of ol/L (P<0.01).GAE and GAW shows to show in this model
The blood uric acid effect of work.
Because uric acid is by kidney excretion, directly related with serum uric acid level, this example is to illustrate to be treated with GAE and GAW
It is probably due to the enhancing of kidney uric acid excretion that serum uric acid level, which reduces, their influences to urine uric acid level is determined, as a result such as Fig. 2
It is shown.Compared with normal group (241 μm of ol/L), model group (187 μm of ol/L, P<0.05) drop of urine uric acid level is observed in
It is low, (78 μm of ol/L, P are administered by allopurinol<0.01) can cause further to reduce urine uric acid content.Benzbromarone 7.8mg/
Kg, GAE be respectively 30,60 and 120mg/kg, GAW 30,60 and 120mg/kg this 7 groups urine uric acid content recover respectively to
232,220,235,227,229,238,280 μm of ol/L (P<0.05).
For influences of the research GAE and GAW to renal function, we also determine hyperuricemia mouse kidney function parameter.Urea
Nitrogen (BUN) is one of renal function leading indicator.Urea nitrogen is the main dead end product of human body protein metabolism, mainly by glomerulus
(important component of kidney) filtration excretes.In kidney function damage early stage, blood urea nitrogen can be in normal range (NR).When kidney is small
When ball filtration rate drops to normal less than 50%, the concentration of blood urea nitrogen just raises rapidly.Therefore, the horizontal reflection of blood urea nitrogen
The situation of renal function：The level of blood urea nitrogen is higher, and the degree of injury of renal function is more serious.As a result as shown in figure 3, due to oxygen
The injury of kidney that the part of piperazine acid potassium and hypoxanthine combination medicine-feeding substitutes the pure administration model of Oteracil Potassium acts on, high lithemia model group
(6.2mmol/L) and normal mouse (6.3mmol/L, P>0.05) the horizontal simultaneously no significant differences of BUN.The BUN of allopurinol group
(11.3mmol/L,P<0.01) it is the 177% of normal control (6.3mmol/L), shows that allopurinol makes hyperuricemia mouse
Impaired renal function.Compared with allopurinol group, it is administered with GAE and GAW various doses, GAE serum BUN parameters are respectively 6.2,
6.5 and 6.8mmol/L, GAW group serum BUN parameters be respectively 8.5,6.8 and 8.8 (P<0.01), substantially less than pair of Allopurinol
According to and difference it is statistically significant.As shown in figure 4, Oteracil Potassium and hypoxanthic administration can make the urine BUN water of normal mouse
Flat (15.86mmol/L, P<0.01) (7.55mmol/L) is reduced.Benzbromarone will urinate the horizontal raisings of BUN to 15.48mmol/L (P
<0.01).Compared with hyperuricemia controls, dosage is respectively horizontal point of the urine BUN of 30,60 and 120mg/kg, GAE administration group
11.40,15.02 and 16.91mmol/L, 30,60 and 120mg/kg are not increased to；GAW is increased to 15.27,11.35 Hes respectively
10.30mmol/L(P<0.01), show that the recovery to kidney organ has certain effect.
Creatinine, it is the end product of metabolism of nitrogenous organic metabolites, by glomerular filtration, is discharged with urine.But renal function by
Loss, creatinine content rise.Therefore creatinine value turns into one of leading indicator of evaluation renal function.As shown in figure 5, hyperuricemia
Model group serum creatinine level is 52.7 μm of ol/L, significant to be higher than normal control (48.5 μm of ol/L, P<0.05).Allopurinol lures
Lead that antihyperuricemic mice serum creatinine levels are significant to be increased to 55.8 μm of ol/L, with Normal group (P<And model group 0.01)
Group compares, the statistically significant (P of difference<0.05), illustrate that allopurinol may damage renal function.With allopurinol group ratio
Compared with GAE and GAW serum creatinine level is respectively 52.2,51.5,47.2,48.4,49.3 and 51.7 μm of ol/ under various dose
L, far below allopurinol group (P<0.01).The result shows that compared with the toxic action of allopurinol GAE and GAW are likely to
Renal function will not be damaged, it is consistent with BUN results.As shown in fig. 6, Oteracil Potassium and hypoxanthine can reduce normal mouse (25.04
μmol/L,P<0.01) and mouse (34.27 μm of ol/L, P are administered in allopurinol<0.01) urine creatinine is horizontal.Various dose
GAE and GAW can be increased to 45.00,44.35,47.37,44.70,45.85 and the creatinine level of hyperuricemia mouse is significant
47.45μmol/L(P<0.01)。
Visceral weight change is a sensitive index, in toxicological experiment, administration group and between administration group
Acropetal coefficient be usually used to assess medicine toxicity size.Each group mouse weight change as shown in fig. 7, with normal group mouse
Compare, the GAE and GAW of all dosage used in this research do not influence body weight, but allopurinol shows in allopurinol group
Suppression body weight increase.The liver coefficient of each group mouse is as shown in figure 8, all equal indifferences for the treatment of group's liver coefficient, illustrate not
Purine alcohol, GAE and GAW are little to liver function influence.The Kidney coefficients of each group mouse are as shown in figure 9, hyperuricemia
(1.52%) and allopurinol group (1.57%) Kidney coefficients are apparently higher than normally (1.35%).In addition, in allopurinol group
It was observed that blister ephritis, but had no in other groups.This shows that Oteracil Potassium and allopurinol have certain damage to renal function
Evil.The GAE Kidney coefficients of various dose are respectively 1.38%, 1.30% and 1.32% (P<0.01), the GAW kidneys of various dose
It is respectively 1.36%, 1.37% and 1.37% (P that coefficient, which is respectively,<0.05) it is, not statistically significant with normal group comparing difference, but
It is lower than hyperuricemia model and allopurinol group, it is little to show that GAE and GAW do not influence or influenceed on renal function.Such as figure
Shown in 10, Spleen coefficient is without significant sex differernce.
The height of uric acid level in XOD (Xanthine oxidase, xanthine oxidase) direct regulation and control human body.Non- purine
Class precursor substance is converted into purines nucleotides by array of biochemical in vivo, continues to decompose generation hypoxanthine and Huang is fast
Purine, eventually pass through XOD continuous oxidation and generate uric acid.It is mainly distributed on liver and small intestine, XOD under high hematuria acid symptom state
Increased activity.XOD Activity Results as shown in FIG. 11 and 12, for the significant height that suppresses of positive control of 5mg/kg dosage urinate by allopurinol
Liver and serum the XOD activity of acidaemia mouse.GAE and GAW does not almost have inhibitory action to XOD.These results can be shown that,
GAE and GAW anti-trioxypurine effect may not be due to XOD activity inhibitory action, and be due to promote hyperuricemia it is small
The uric acid excretion effect of mouse.
In addition, we have detected Ganoderma applanatum (Pers. Ex Wallr) Pat. extract to kidney by westernbloting (western blot analysis)
The influence of OAT1, GLUT9 and URAT1 protein level, as a result as shown in figure 13.OAT1 protein expression level analysis result is as schemed
Shown in 14, the OAT1 that GAE and GAW are improved in hyperuricemia kidney of mouse is expressed.Compared with model group, GAE and GAW-
Treat the significant rise of OAT1 protein expressions of mouse.GLUT9 and URAT1 protein expression level analysis result respectively such as Figure 15 and
Shown in 16, compared with normal mouse, Oteracil Potassium and hypoxanthine induction hyperuricemia mouse develop into kidney GLUT9 and
The horizontal significant rise (P of URAT1<0.01).The significant reduction (P of GAE and GAW group GLUT9 expressions<0.01).7.8mg/kg
Benzbromarone can reduce hyperuricemia mouse kidney Urine proteins URAT1 expression (P<0.05).It is similar with Benzbromarone, GAE
Significant reduction URAT1 protein levels (P<0.01), and GAW does not show this effect.
We also have detected expression of the Ganoderma applanatum (Pers. Ex Wallr) Pat. extract to mouse intestinal transport protein CNT2 by westernbloting
Situation, as a result as shown in FIG. 17 and 18, it is found that two kinds of Ganoderma applanatum (Pers. Ex Wallr) Pat. extracts can lower intestinal transporter CNT2 expression
The above results illustrate that Ganoderma applanatum (Pers. Ex Wallr) Pat. extract of the present invention has good anti-trioxypurine effect, and its anti-trioxypurine effect can make
High lithemia model group blood uric acid concentration is brought down below normal mouse uric acid level, and these effects are to adjust kidney by GAE to transport
Albumen OAT1, GLUT9 and URAT1 and intestines and stomach CNT2 and GAW regulation kidney transport protein OAT1 and GLUT9 intestines and stomach CNT2 institutes
Mediation.In addition, Ganoderma applanatum (Pers. Ex Wallr) Pat. extract can be used for preparing anti-trioxypurine, improve the medicine of gout, protect to the equal nontoxicity of liver,kidney,spleen
In strong product or assistant medicament.
Finally, it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention rather than the present invention is protected
The limitation of scope is protected, although being explained in detail with reference to preferred embodiment to the present invention, one of ordinary skill in the art should
Understand, technical scheme can be modified or equivalent substitution, without departing from the essence of technical solution of the present invention
And scope.
Claims (10)
1. a kind of preparation method of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract, it is characterised in that comprise the following steps：
(1) dry artist's conk fructification is crushed；
(2) 0.5-5 hours are extracted with 5-25 times of ethanol at 40-75 DEG C, is filtered under diminished pressure separation filter residue and filtrate, in triplicate；
(3) it is evaporated under reduced pressure after the filtrate obtained by step (2) is merged and is concentrated into 25-250mL, alcohol extract is obtained after drying；
(4) 40-100 DEG C by the use of water as solvent extraction alcohol extracting after artist's conk residue 0.5-3 hours, after be filtered under diminished pressure separation filter residue
And filtrate, identical condition is in triplicate；
(5) it is evaporated under reduced pressure after the filtrate obtained by step (4) is merged and is concentrated into 25-250mL, water extract is obtained after drying.
2. the preparation method of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract as claimed in claim 1, it is characterised in that the Extracting temperature in the step (2)
For 60 DEG C；Extracting temperature in step (4) is 85 DEG C.
3. the preparation method of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract as claimed in claim 1, it is characterised in that the extraction in the step (2) and (4)
Process is ultrasonic extraction.
4. a kind of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract, it is characterised in that the Ganoderma applanatum (Pers. Ex Wallr) Pat. extract uses the system as described in any one of claims 1 to 3
Preparation Method is prepared.
5. Ganoderma applanatum (Pers. Ex Wallr) Pat. extract as claimed in claim 4, it is characterised in that in the Ganoderma applanatum (Pers. Ex Wallr) Pat. extract, triterpene total content is 100
~10000 μ g/g.
6. application of the Ganoderma applanatum (Pers. Ex Wallr) Pat. extract in anti-trioxypurine, the medicine for improving gout illness, health products or ancillary drug is prepared.
7. application as claimed in claim 6, it is characterised in that the Ganoderma applanatum (Pers. Ex Wallr) Pat. extract is prepared with the following method：
(1) dry artist's conk fructification is crushed；
(2) 0.5-5 hours are extracted with 5-25 times of ethanol at 40-75 DEG C, is filtered under diminished pressure separation filter residue and filtrate, in triplicate；
(3) it is evaporated under reduced pressure after the filtrate obtained by step (2) is merged and is concentrated into 25-250mL, alcohol extract is obtained after drying；
(4) 40-100 DEG C by the use of water as solvent extraction alcohol extracting after artist's conk residue 0.5-3 hours, after be filtered under diminished pressure separation filter residue
And filtrate, identical condition is in triplicate；
(5) it is evaporated under reduced pressure after the filtrate obtained by step (4) is merged and is concentrated into 25-250mL, water extract is obtained after drying.
8. application as claimed in claim 7, it is characterised in that the Extracting temperature in rapid (2) is 60 DEG C；In step (4)
Extracting temperature be 85 DEG C.
9. application as claimed in claim 7, it is characterised in that the extraction process in the step (2) and (4) carries for ultrasound
Take.
10. a kind of medicine for treating goat, it is characterised in that the artist's conk that the medicine contains as described in claim 4 or 5 carries
Take thing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711180533.2A CN107669711B (en) | 2017-11-23 | 2017-11-23 | Pharmaceutical application of Ganoderma applanatum extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711180533.2A CN107669711B (en) | 2017-11-23 | 2017-11-23 | Pharmaceutical application of Ganoderma applanatum extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107669711A true CN107669711A (en) | 2018-02-09 |
| CN107669711B CN107669711B (en) | 2020-11-03 |
Family
ID=61150451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711180533.2A Active CN107669711B (en) | 2017-11-23 | 2017-11-23 | Pharmaceutical application of Ganoderma applanatum extract |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107669711B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578443A (en) * | 2018-03-05 | 2018-09-28 | 广东省微生物研究所（广东省微生物分析检测中心） | The preparation method of armillaria mellea and its application in terms of anti-trioxypurine |
| CN109200069A (en) * | 2018-10-08 | 2019-01-15 | 浙江理工大学 | Ganoderma lipsiense ethanol extract and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013142074A (en) * | 2012-01-11 | 2013-07-22 | Hitoshi Ito | Uric acid value increase inhibitor and food and drink having uric acid value increase inhibiting action |
| CN106901326A (en) * | 2017-03-15 | 2017-06-30 | 福建农林大学 | A kind of preparation and application of ganoderma lipsiense full agonist |
| CN107260769A (en) * | 2016-04-07 | 2017-10-20 | 杨小渝 | A kind of tumour, hypoglycemic for the treatment of is dispelled the Chinese medicine of gout |
-
2017
- 2017-11-23 CN CN201711180533.2A patent/CN107669711B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013142074A (en) * | 2012-01-11 | 2013-07-22 | Hitoshi Ito | Uric acid value increase inhibitor and food and drink having uric acid value increase inhibiting action |
| CN107260769A (en) * | 2016-04-07 | 2017-10-20 | 杨小渝 | A kind of tumour, hypoglycemic for the treatment of is dispelled the Chinese medicine of gout |
| CN106901326A (en) * | 2017-03-15 | 2017-06-30 | 福建农林大学 | A kind of preparation and application of ganoderma lipsiense full agonist |
Non-Patent Citations (2)
| Title |
|---|
| 《正本清源》栏目组: "《走进中医世界，领略中药魅力》", 30 June 2014, 中国中医药出版社 * |
| 王娇: "超声提取海南树舌灵芝多糖工艺参数的响应面优化", 《南华大学学报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578443A (en) * | 2018-03-05 | 2018-09-28 | 广东省微生物研究所（广东省微生物分析检测中心） | The preparation method of armillaria mellea and its application in terms of anti-trioxypurine |
| CN109200069A (en) * | 2018-10-08 | 2019-01-15 | 浙江理工大学 | Ganoderma lipsiense ethanol extract and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107669711B (en) | 2020-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104473977B (en) | A kind of Cordyceps militaris water extract, preparation method and applications | |
| CN109010414A (en) | Ramulus Et Folium Pithecellobii Lucidi extract is preventing and/or is treating the application in hyperuricemia and metabolic disorder relevant to hyperuricemia | |
| WO2006026926A1 (en) | A medicinal composition for treating hepatic fibrosis and its preparation | |
| CN107669711A (en) | The preparation method and its usage of Ganoderma applanatum (Pers. Ex Wallr) Pat. extract | |
| CN105125566B (en) | The application of mannoglucan aldehydic acid oligosaccharides and derivative in treatment and/or prevention nephrosis medicine or health products is prepared | |
| KR20010049156A (en) | The extract of pine needle and the use thereof | |
| CN109939153A (en) | A kind of anaesthetic for treating enteritis and preparation method thereof and preparation and preparation method | |
| CN105999217B (en) | Composition for preventing and treating hyperuricemia and preparation method and application thereof | |
| CN108403729B (en) | Preparation method of agrocybe cylindracea extract and application of agrocybe cylindracea extract in preparation of uric acid reducing medicine | |
| CN109999079A (en) | The preparation method of radix fici simplicissimatis extractive and the application in terms of preparing treatment/prevention high lithemia related disease medicine/health product | |
| CN112807375B (en) | Application of Wangshi Baochi pill in preparation of medicine for preventing and/or treating alcoholic liver injury | |
| CN110051706A (en) | The preparation method of extract of Zhuling and its application in terms of preparing treatment/prevention high lithemia related disease medicine/health product | |
| CN103417907B (en) | A kind of application of Chinese medicine composition in the medicine for suppressing angiogenesis is prepared | |
| CN104997843A (en) | Application of selfheal extract for making blood uric acid decreasing medicine or food | |
| CN101904856A (en) | Application of 1,6-diphosphofructose and derivative thereof in preparing animal medical health care products | |
| Djabir et al. | The protective effect of Paliasa (Kleinhovia hospita L.) leaf extract against elevated total bilirubin serum induced by toxic dose of antituberculosis in rats | |
| CN109758497B (en) | Traditional Chinese medicine composition and medicine for chronic heart failure and preparation method and application thereof | |
| CN108379455B (en) | Uric acid reducing composition | |
| CN106038562A (en) | Medicine for treating rheumatoid arthritis | |
| CN109512845A (en) | Application of the Inonotus obliquus alcohol extracting thing in terms of preparing treatment/prevention high lithemia related disease medicine/health product | |
| CN109394798B (en) | Preparation method of dried extract of xanthobacter guidongensis and application of dried extract in reducing uric acid | |
| CN108379379A (en) | Chinese medicine composition for acute stage of gout | |
| CN112386641B (en) | Traditional Chinese medicine composition for treating pulmonary tuberculosis and preparation method and traditional Chinese medicine preparation thereof | |
| WO2022135462A1 (en) | Medicinal use of magl inhibitor | |
| CN108578443A (en) | The preparation method of armillaria mellea and its application in terms of anti-trioxypurine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: No. 56, courtyard, No. 100, Xianlie Middle Road, Guangzhou, Guangdong 510070 Patentee after: GUANGDONG INSTITUTE OF MICROBIOLOGY (GUANGDONG DETECTION CENTER OF MICROBIOLOGY) Patentee after: GUANGDONG YUEWEI EDIBLE FUNGI TECHNOLOGY Co.,Ltd. Address before: 510075 courtyard, No. 100, Xianlie Middle Road, Yuexiu District, Guangzhou City, Guangdong Province Patentee before: GUANGDONG INSTITUTE OF MICROBIOLOGY Patentee before: GUANGDONG YUEWEI EDIBLE FUNGI TECHNOLOGY Co.,Ltd. Address after: 510070 No. 58, courtyard, No. 100, Xianlie Middle Road, Yuexiu District, Guangzhou, Guangdong Province Patentee after: Institute of Microbiology, Guangdong Academy of Sciences Patentee after: GUANGDONG YUEWEI EDIBLE FUNGI TECHNOLOGY Co.,Ltd. Address before: No. 56, courtyard, No. 100, Xianlie Middle Road, Guangzhou, Guangdong 510070 Patentee before: GUANGDONG INSTITUTE OF MICROBIOLOGY (GUANGDONG DETECTION CENTER OF MICROBIOLOGY) Patentee before: GUANGDONG YUEWEI EDIBLE FUNGI TECHNOLOGY Co.,Ltd. |
|
| CP03 | Change of name, title or address |